Appendix 4D HALF-YEAR REPORT

BLACKMORES | GROUP

Blackmores Limited - ACN 009 713 437 (**the Company**) For the period ended 31 December 2022

This Half-Year Report is provided to the Australian Stock Exchange (ASX) under ASX Listing Rule 4.2A

RESULTS FOR ANNOUNCEMENT TO THE MARKET

Current Reporting Period: Half-Year ended 31 December 2022

Previous Corresponding Period: Half-Year ended 31 December 2021

Revenue and Net Profit	Up/Down	Movement	31/12/2022 Amount \$'000	31/12/2021 Amount \$'000	
Revenue from ordinary activities ¹	Down	1.6% to	338,023	343,643	
Profit after tax attributable to members ²	Up	19.6% to	24,288	20,303	
Net profit attributable to members ²	Up	19.6% to	24,288	20,303	
Dividend Information		Amount		Franked Amount	
Interim dividend per ordinary share		87 cents		87 cents	

Record date for determining entitlements to the interim dividend:

Record date 9 March 2023 and payable 28 March 2023

Dividend Reinvestment Plan

The Company's Dividend Reinvestment Plan (DRP) will not apply to the interim dividend.

Other Financial Information	31/12/2022	31/12/2021	
Net tangible asset backing per share	\$16.95	\$15.05	

Additional Appendix 4D disclosure requirements can be found in the Blackmores Limited Half-Year Report for the period ended 31 December 2022. The Appendix 4D is based on the Blackmores Limited Half-Year Report for the period ended 31 December 2022 which has been reviewed by Deloitte Touche Tohmatsu. This should be read in conjunction with the most recent Annual Financial Report as at and for the year ended 30 June 2022.

^{1.} The Group has reviewed co-marketing arrangements with customers, previously disclosed as part of Selling and marketing expenses, and to the extent that the consideration payable to a customer is not a payment for a distinct good or service and is in excess of the fair value, then the Group will treat the payment as part of Trade spend, promotional and other rebates, which is offset against Revenue. Prior comparative financial information has been reclassified, resulting in a \$2.4m reduction in Revenue and a corresponding reduction in Selling and marketing expenses.

^{2.} Profit after tax attributable to members and Net profit attributable to members excludes 49.9% of the profit or loss attributable to the non-controlling interest held by our Indonesian Joint Venture Partner, PT Sanghiang Perkasa, a subsidiary entity of the PT Kalbe Farma Tbk Group.